Market Research Reports, Inc.

Asthma Drugs Market in the US to Grow at a CAGR of 4.64% over the Period 2014 - 2019; Finds New Report

Market Research Reports, Inc. has announced the addition of “Asthma Drugs Market in the US 2015-2019” research report to their website


Lewes, DE -- (SBWIRE) -- 06/24/2015 -- Report forecast the asthma drugs market in the US to grow at a CAGR of 4.64% over the period 2014-2019.

Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors. The American Academy of Allergy Asthma and Immunology classifies asthma under four categories: exercise-induced asthma, allergic asthma, occupational asthma, and childhood asthma. The Asthma and Allergy Foundation of America classifies asthma into two categories: allergic asthma and non-allergic asthma. It is an incurable disease but can be controlled with the help of diagnosis at the right time, followed by regular therapy.

This report covers the present scenario and the growth prospects of the asthma drugs market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sale of various classes of drugs used to treat asthma, which include:

- Bronchodilators
- Leukotriene antagonists
- Mast cell stabilizers
- Immunosuppressants
- Combination of LABA/ICS

According to the report, pharmaceutical companies are developing drugs that have a better safety and efficacy profile than those already available in the market. These drugs are undergoing clinical trials or are awaiting approval by regulatory agencies. For instance, NVA237 by Novartis and Mepolizumab by GlaxoSmithKline are among the most promising drugs for the treatment of asthma. Mepolizumab by GlaxoSmithKline was submitted for approval as a maintenance treatment for severe eosinophilic asthma to the US Food and Drug Administration (FDA) in November 2014. Tralokinumab by AstraZeneca is another promising molecule, which is under phase III clinical trials.

Further, the report states that the unknown etiology of the condition makes it difficult for pharmaceutical companies to develop a curative drug for the treatment of asthma.

Asthma Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the asthma drugs market in the US: AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline and Merck

Other Prominent Vendors in the market are: Abbott Laboratories, Addex Therapeutics, Alkermes, AstraZeneca, Aurobindo Pharma, Avanir Pharmaceuticals, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre Kramer, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Naurex, Neuralstem, Novartis, Opko Health, Otsuka Pharmaceutical, Pierre Fabre, Shire, SK Biopharmaceuticals, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Suven, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals and Valeant Pharmaceuticals

Market driver
- Rise in disease prevalence
- For a full, detailed list, view our report

Market challenge
- Unknown disease etiology
- For a full, detailed list, view our report

Market trend
- Popularity of combination therapies
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 103 pages and 49 Exhibits "Asthma Drugs Market in the US 2015-2019" report covers Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Disease Overview, Pipeline Portfolio, Market Landscape, Market Segmentation by Class of Drug, Bronchodilators, Combination of LABA/ICS, Immunosuppressants, Leukotriene Antagonists, Mast Cell Stabilizers, Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and Their Impact, Vendor Landscape, Key Vendor Analysis.

For further information on this report, please visit-

Find all Drug Delivery Reports at:

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: